EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Irisin ameliorates age‐associated sarcopenia and metabolic dysfunction

Mingwei Guo, Jing Yao, Jin Li, Jun Zhang, Dongmei Wang, Hui Zuo, Yi Zhang, Bo Xu, Yinzhao Zhong, Fei Shen, Jian Lu, Shuzhe Ding und 4 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2023-02 · 14 (1) · 391-405

DOI: 10.1002/jcsm.13141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 12.12.2022. Verfasst von Mingwei Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, …. Hauptthemen laut MEDLINE: Sarcopenia. Die Arbeit wurde bisher 175-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Science and Technology Commission of Shanghai Municipality, Innovative research team of high-level local universities in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Age‐associated sarcopenia is characterized of progressed loss of skeletal muscle power, mass, and function, which affects human physical activity and life quality. Besides, accompanied with sarcopenia, aged population also faces a series of metabolic dysfunctions. Irisin, the cleaved form of fibronectin type III domain‐containing protein 5 (FNDC5), is a myokine induced by exercise and has been shown to exert multiple beneficial effects on health. The goal of the study is to investigate the alterations of Fndc5/irisin in skeletal muscles during ageing and whether irisin administration could ameliorate age‐associated sarcopenia and metabolic dysfunction.

Methods

The mRNA and protein levels of FNDC5/irisin in skeletal muscle and serum from 2‐ and 24‐month‐old mice or human subjects were analysed using qRT‐PCR and western blot. FNDC5/irisin knockout mice were generated to investigate the consequences of FNDC5/irisin deletion on skeletal muscle mass, as well as morphological and molecular changes in muscle during ageing via histological and molecular analysis. To identify the therapeutic effects of chronic irisin treatment in mice during ageing, in vivo intraperitoneal administration of 2 mg/kg recombinant irisin was performed three times per week in ageing mice (14‐month‐old) for 4 months or in aged mice (22‐month‐old) for 1 month to systematically investigate irisin's effects on age‐associated sarcopenia and metabolic performances, including grip strength, body weights, body composition, insulin sensitivity, energy expenditure, serum parameters and phenotypical and molecular changes in fat and liver.

Results

We showed that the expression levels of irisin, as well as its precursor Fndc5, were reduced at mRNA and protein expression levels in muscle during ageing. In addition, via phenotypic analysis of FNDC5/irisin knockout mice, we found that FNDC5/irisin deficiency in aged mice exhibited aggravated muscle atrophy including smaller grip strength (−3.23%, P < 0.05), muscle weights (quadriceps femoris [QU]: −20.05%; gastrocnemius [GAS]: −17.91%; tibialis anterior [TA]: −19.51%, all P < 0.05), fibre size (QU: P < 0.01) and worse molecular phenotypes compared with wild‐type mice. We then delivered recombinant irisin protein intraperitoneally into ageing or aged mice and found that it could improve sarcopenia with grip strength (+18.42%, P < 0.01 or +13.88%, P < 0.01), muscle weights (QU: +9.02%, P < 0.01 or +16.39%, P < 0.05), fibre size (QU: both P < 0.05) and molecular phenotypes and alleviated age‐associated fat tissues expansion, insulin resistance and hepatic steatosis (all P < 0.05), accompanied with altered gene signatures.

Conclusions

Together, this study revealed the importance of irisin in the maintenance of muscle physiology and systematic energy homeostasis during ageing and suggested a potent therapeutic strategy against age‐associated metabolic diseases via irisin administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaAnimalsMiceFibronectinsMice, KnockoutRNA, MessengerTranscription Factors

Stichwörter der Autor:innen

FNDC5ageingirisinmetabolic dysfunctionsarcopenia

Substanzen

FibronectinsFNDC5 protein, mouseRNA, MessengerTranscription Factors

Autor:innen und Institutionen

  • Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, China.
  • Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
  • Key Laboratory of Adolescent Health Assessment and Exercise Intervention of Ministry of Education, College of Physical Education and Health, East China Normal University, Shanghai, China.
  • Department of Endocrinology and Metabolism, Fengxian Central Hospital Affiliated to Southern Medical University, Shanghai, China.
  • Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, China.

Förderung

  • National Key Research and Development Program of China
  • Science and Technology Commission of Shanghai Municipality
  • Innovative research team of high-level local universities in Shanghai
  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing, China
  • Fundamental Research Funds for the Central Universities
  • ECNU public platform for Innovation
  • School of Life Sciences, East China Normal University

Zitieren

APA

Guo, M., Yao, J., Li, J., Zhang, J., Wang, D., Zuo, H., Zhang, Y., Xu, B., Zhong, Y., Shen, F., Lu, J., Ding, S., Hu, C., Xu, L., Xiao, J., & Ma, X. (2023). Irisin ameliorates age‐associated sarcopenia and metabolic dysfunction. Journal of Cachexia, Sarcopenia and Muscle, 14(1), 391-405. https://doi.org/10.1002/jcsm.13141

Vancouver

Guo M, Yao J, Li J, Zhang J, Wang D, Zuo H, et al. Irisin ameliorates age‐associated sarcopenia and metabolic dysfunction. Journal of Cachexia, Sarcopenia and Muscle. 2023;14(1):391-405. doi:10.1002/jcsm.13141

BibTeX
@article{Guo2023,
  author = {Guo, Mingwei and Yao, Jing and Li, Jin and Zhang, Jun and Wang, Dongmei and Zuo, Hui and Zhang, Yi and Xu, Bo and Zhong, Yinzhao and Shen, Fei and Lu, Jian and Ding, Shuzhe and Hu, Cheng and Xu, Lingyan and Xiao, Junjie and Ma, Xinran},
  title = {Irisin ameliorates age‐associated sarcopenia and metabolic dysfunction},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2023},
  volume = {14},
  number = {1},
  pages = {391--405},
  doi = {10.1002/jcsm.13141}
}
Kostenlos starten →